Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-4

Breakeven gets closer but one feels one more capital raise will be required before they get there.

"Cash reserves are $1.7m at the end of September 2024. The FY24 R&D incentive refund is being finalised
for lodgement with the ATO, and if required, financing of up to 80%, or approximately $950,000 can be
made available against that refund. If the company draws on that financing, then operations can continue
for up to two quarters with a continuation of current run rates and completion of payments for US FDA
submission (see below). The company is currently finalising arrangements to make that financing
available, and is exploring further financing options. The company has successfully raised funds from
investors and current shareholders in the past, and expects this support to continue going forward."